Mannose receptor is an HIV restriction factor counteracted by Vpr in macrophages.
Gene Products, env
/ metabolism
Gene Products, nef
/ metabolism
HIV-1
/ metabolism
Humans
Lectins, C-Type
/ metabolism
Macrophages
/ metabolism
Mannose Receptor
Mannose-Binding Lectins
/ metabolism
Protein Binding
Receptors, Cell Surface
/ metabolism
Virus Replication
vpr Gene Products, Human Immunodeficiency Virus
/ metabolism
HIV
Nef
Vpr
human
immunology
infectious disease
inflammation
macrophages
mannose receptor
microbiology
restriction factor
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
02 03 2020
02 03 2020
Historique:
received:
12
08
2019
accepted:
25
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
24
4
2021
Statut:
epublish
Résumé
HIV-1 Vpr is necessary for maximal HIV infection and spread in macrophages. Evolutionary conservation of Vpr suggests an important yet poorly understood role for macrophages in HIV pathogenesis. Vpr counteracts a previously unknown macrophage-specific restriction factor that targets and reduces the expression of HIV Env. Here, we report that the macrophage mannose receptor (MR), is a restriction factor targeting Env in primary human monocyte-derived macrophages. Vpr acts synergistically with HIV Nef to target distinct stages of the MR biosynthetic pathway and dramatically reduce MR expression. Silencing MR or deleting mannose residues on Env rescues Env expression in HIV-1-infected macrophages lacking Vpr. However, we also show that disrupting interactions between Env and MR reduces initial infection of macrophages by cell-free virus. Together these results reveal a Vpr-Nef-Env axis that hijacks a host mannose-MR response system to facilitate infection while evading MR's normal role, which is to trap and destroy mannose-expressing pathogens. Human cells have defense mechanisms against viral infection known as restriction factors. These are proteins that break down parts of a virus including its DNA or proteins. To evade these defenses, viruses in turn make proteins that block or break down restriction factors. This battle between human and viral proteins determines which types of cells are infected and how quickly a virus can multiply and spread to new cells. HIV produces a protein called Vpr that counteracts a restriction factor found in immune cells called macrophages. However, the identity of the restriction factor targeted by Vpr is a mystery. When Vpr is missing, this unknown restriction factor breaks down a virus protein called Env. Env is a glycoprotein, which is a protein with sugars attached. When Env levels are low, HIV cannot spread to other cells and multiply. Identifying the restriction factor that breaks down Env may lead to new ways of treating and preventing HIV infections. Now, Lubow et al. reveal that the unknown restriction factor in macrophages is a protein called the mannose receptor. This protein binds and destroys proteins containing mannose, a type of sugar found on bacteria and some viruses. The experiments revealed that the mannose receptor grabs mannose on the HIV protein Env. This causes Env to be broken down and stops HIV from spreading. Lubow et al. also find that Vpr works with another protein produced by HIV called Nef to reduce the number of mannose receptors on macrophages. The two proteins do this by targeting different steps in the assembly of mannose receptors, allowing the virus to multiply and spread more efficiently. The experiments suggest that drugs that simultaneously block Vpr and Nef might prevent or suppress HIV infections. More studies are needed to develop and test potential HIV-treatments targeting Vpr and Nef.
Autres résumés
Type: plain-language-summary
(eng)
Human cells have defense mechanisms against viral infection known as restriction factors. These are proteins that break down parts of a virus including its DNA or proteins. To evade these defenses, viruses in turn make proteins that block or break down restriction factors. This battle between human and viral proteins determines which types of cells are infected and how quickly a virus can multiply and spread to new cells. HIV produces a protein called Vpr that counteracts a restriction factor found in immune cells called macrophages. However, the identity of the restriction factor targeted by Vpr is a mystery. When Vpr is missing, this unknown restriction factor breaks down a virus protein called Env. Env is a glycoprotein, which is a protein with sugars attached. When Env levels are low, HIV cannot spread to other cells and multiply. Identifying the restriction factor that breaks down Env may lead to new ways of treating and preventing HIV infections. Now, Lubow et al. reveal that the unknown restriction factor in macrophages is a protein called the mannose receptor. This protein binds and destroys proteins containing mannose, a type of sugar found on bacteria and some viruses. The experiments revealed that the mannose receptor grabs mannose on the HIV protein Env. This causes Env to be broken down and stops HIV from spreading. Lubow et al. also find that Vpr works with another protein produced by HIV called Nef to reduce the number of mannose receptors on macrophages. The two proteins do this by targeting different steps in the assembly of mannose receptors, allowing the virus to multiply and spread more efficiently. The experiments suggest that drugs that simultaneously block Vpr and Nef might prevent or suppress HIV infections. More studies are needed to develop and test potential HIV-treatments targeting Vpr and Nef.
Identifiants
pubmed: 32119644
doi: 10.7554/eLife.51035
pii: 51035
pmc: PMC7051176
doi:
pii:
Substances chimiques
Gene Products, env
0
Gene Products, nef
0
Lectins, C-Type
0
Mannose Receptor
0
Mannose-Binding Lectins
0
Receptors, Cell Surface
0
vpr Gene Products, Human Immunodeficiency Virus
0
vpr protein, Human immunodeficiency virus 1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R21 AI132379
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI130004
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI120954
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM145304
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32GM008353-28
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007863
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI051192
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI046998
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI125090
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007413
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007315
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008353
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007528
Pays : United States
Informations de copyright
© 2020, Lubow et al.
Déclaration de conflit d'intérêts
JL, MV, MM, DC, MM, BP, ZL, MP, FG, VT, GZ, KC No competing interests declared
Références
DNA Repair (Amst). 2010 Jul 1;9(7):785-95
pubmed: 20466601
Nat Rev Microbiol. 2007 Aug;5(8):583-97
pubmed: 17632570
Glycobiology. 2006 May;16(5):422-30
pubmed: 16423983
PLoS Pathog. 2015 Jul 17;11(7):e1005054
pubmed: 26186441
J Virol. 2001 Nov;75(22):10892-905
pubmed: 11602729
J Virol. 2005 Sep;79(17):10978-87
pubmed: 16103149
J Immunol. 1992 May 15;148(10):3055-61
pubmed: 1374448
J Virol. 1992 Dec;66(12):7517-21
pubmed: 1433527
J Virol. 1996 Feb;70(2):1100-8
pubmed: 8551569
Mol Cell Biol. 2008 Sep;28(18):5621-33
pubmed: 18606781
J Biol Chem. 2007 Sep 14;282(37):27046-57
pubmed: 17620334
J Virol. 1999 Mar;73(3):1828-34
pubmed: 9971760
Cell. 2014 Jan 16;156(1-2):134-45
pubmed: 24412650
Cell Host Microbe. 2014 Dec 10;16(6):722-35
pubmed: 25464830
J Biol Chem. 1990 Jun 25;265(18):10373-82
pubmed: 2355006
J Virol. 1993 Nov;67(11):6542-50
pubmed: 8411357
J Virol. 2004 Apr;78(8):4120-33
pubmed: 15047828
J Biol Chem. 1989 Feb 5;264(4):2385-90
pubmed: 2914913
Nature. 2014 Nov 6;515(7525):138-42
pubmed: 25186731
J Virol. 2004 Feb;78(4):1718-29
pubmed: 14747537
J Exp Med. 1999 Jun 21;189(12):1961-72
pubmed: 10377192
Curr Biol. 1999 Jun 17;9(12):613-21
pubmed: 10375525
J Virol. 2004 Nov;78(22):12689-93
pubmed: 15507658
J Biol Chem. 2012 Nov 30;287(49):40875-83
pubmed: 23043100
J Virol. 2016 Nov 28;90(24):11132-11144
pubmed: 27707925
J Virol. 1990 Jun;64(6):3097-9
pubmed: 2139896
Proc Natl Acad Sci U S A. 2016 May 10;113(19):5311-6
pubmed: 27114546
Virology. 1995 Feb 1;206(2):935-44
pubmed: 7531918
J Virol. 2002 Jul;76(14):7293-305
pubmed: 12072528
Chest. 1993 Feb;103(2 Suppl):111S-112S
pubmed: 8428526
J Virol. 2002 Jul;76(14):7306-21
pubmed: 12072529
Gene. 1983 Dec;26(1):101-6
pubmed: 6323249
J Clin Invest. 1998 Oct 1;102(7):1332-44
pubmed: 9769325
Cell. 2016 May 5;165(4):813-26
pubmed: 27114034
J Virol. 2012 Sep;86(17):9337-50
pubmed: 22718820
J Leukoc Biol. 2005 Apr;77(4):522-34
pubmed: 15637102
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
Mol Biol Cell. 2006 Aug;17(8):3578-90
pubmed: 16775006
AIDS Res Hum Retroviruses. 1994 Apr;10(4):371-81
pubmed: 8068416
Nat Commun. 2015 Jun 24;6:7479
pubmed: 26105115
J Immunol. 2000 Dec 15;165(12):7035-41
pubmed: 11120831
J Virol. 1991 Aug;65(8):3973-85
pubmed: 1830110
J Virol. 2005 Jul;79(13):8629-36
pubmed: 15956605
Curr Biol. 2005 Apr 26;15(8):714-23
pubmed: 15854903
J Neuroimmune Pharmacol. 2014 Dec;9(5):716-26
pubmed: 25146376
J Virol. 1993 Aug;67(8):4639-50
pubmed: 8043040
Blood. 1991 Mar 1;77(5):1111-7
pubmed: 1995097
BMC Microbiol. 2014 Aug 02;14:211
pubmed: 25085553
Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11778-83
pubmed: 17609381
J Virol. 1995 Jul;69(7):4413-22
pubmed: 7769703
Cell. 1994 Mar 11;76(5):853-64
pubmed: 8124721
Immunity. 1999 Sep;11(3):281-8
pubmed: 10514006
Curr Biol. 1998 Nov 5;8(22):1235-8
pubmed: 9811606
AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69
pubmed: 7520721
Antimicrob Agents Chemother. 2000 Jun;44(6):1667-73
pubmed: 10817726
Retrovirology. 2011 Jun 22;8:49
pubmed: 21696578
Nat Struct Mol Biol. 2016 Oct;23(10):933-940
pubmed: 27571178
J Virol. 1996 Sep;70(9):6044-53
pubmed: 8709227
Cell Cycle. 2007 Jan 15;6(2):182-8
pubmed: 17314515
J Biol Chem. 2009 Apr 24;284(17):11027-38
pubmed: 19224860
Curr Biol. 1998 Nov 5;8(22):1239-42
pubmed: 9811611
J Virol. 2006 Nov;80(22):11141-52
pubmed: 16928758
Nat Microbiol. 2019 Jan;4(1):62-70
pubmed: 30420782
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4130-5
pubmed: 17360488
Biochim Biophys Acta. 1996 Mar 13;1279(2):227-34
pubmed: 8603091
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5097-102
pubmed: 17360361
J Biol Chem. 1978 Aug 25;253(16):5600-12
pubmed: 209045
J Immunol. 1997 Sep 1;159(5):2462-7
pubmed: 9278339
Curr Biol. 1999 Jun 17;9(12):622-31
pubmed: 10375528
J Virol. 2011 Jul;85(14):6867-81
pubmed: 21543478
J Biol Chem. 2016 Aug 12;291(33):16936-16947
pubmed: 27354282
Cell. 1980 Jan;19(1):207-15
pubmed: 6766809
J Virol. 2012 Mar;86(5):2715-28
pubmed: 22190722
Eur J Immunol. 2003 Feb;33(2):483-93
pubmed: 12645947
Eur J Med Res. 2007 Oct 15;12(9):409-17
pubmed: 17933722
Viruses. 2012 Dec 21;5(1):1-14
pubmed: 23344558
PLoS Pathog. 2007 Jul;3(7):e85
pubmed: 17630831
Nat Med. 2010 Apr;16(4):446-51
pubmed: 20208541
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):389-97
pubmed: 18614929
Curr Opin Immunol. 1998 Feb;10(1):50-5
pubmed: 9523111
Virology. 1994 May 1;200(2):623-31
pubmed: 8178448
Cell Rep. 2018 Jan 16;22(3):786-795
pubmed: 29346774
J Virol. 1995 Aug;69(8):4807-13
pubmed: 7609047
J Exp Med. 2001 Nov 19;194(10):1407-19
pubmed: 11714748